MiNK Therapeutics, UnitedHealth Group, and Eli Lilly and Company are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies operating in the healthcare sector, including pharmaceutical firms, biotech developers and medical device manufacturers. By purchasing these stocks, investors gain exposure to the research, development and distribution of medical products and services. Their performance is driven by factors such as clinical trial outcomes, regulatory approvals, healthcare policy changes and demographic shifts. These companies had the highest dollar trading volume of any Medical stocks within the last several days.
MiNK Therapeutics (INKT)
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.
INKT traded up $59.68 on Friday, hitting $67.41. 33,406,767 shares of the company were exchanged, compared to its average volume of 153,238. MiNK Therapeutics has a 12 month low of $4.56 and a 12 month high of $72.94. The firm has a fifty day simple moving average of $7.32 and a two-hundred day simple moving average of $8.02. The stock has a market capitalization of $268.70 million, a PE ratio of -27.86 and a beta of 0.19.
Read Our Latest Research Report on INKT
UnitedHealth Group (UNH)
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.
Shares of NYSE UNH traded up $0.71 during mid-day trading on Friday, hitting $300.22. The stock had a trading volume of 4,357,055 shares, compared to its average volume of 7,649,725. The firm has a market cap of $272.34 billion, a P/E ratio of 12.58, a price-to-earnings-growth ratio of 1.45 and a beta of 0.45. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.85 and a current ratio of 0.85. The business has a 50 day moving average price of $316.42 and a two-hundred day moving average price of $442.28. UnitedHealth Group has a 1 year low of $248.88 and a 1 year high of $630.73.
Read Our Latest Research Report on UNH
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of LLY stock traded down $9.38 during mid-day trading on Friday, reaching $781.27. The stock had a trading volume of 1,390,020 shares, compared to its average volume of 3,661,339. The stock's 50-day moving average price is $767.03 and its two-hundred day moving average price is $800.01. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The firm has a market capitalization of $740.44 billion, a PE ratio of 63.54, a price-to-earnings-growth ratio of 1.15 and a beta of 0.40. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18.
Read Our Latest Research Report on LLY
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MiNK Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiNK Therapeutics wasn't on the list.
While MiNK Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
